ISRCTN18390621已完成未知
Clinical assessment of a combined treatment targeting subjects with acne-prone skin
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
2022 Results article in https://dx.doi.org/10.7241/ourd.20223.1 (added 18/07/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Good general health
- •2. Both sexes, caucasian ethnicity
- •3. Phototype I to IV
- •4. Age between 18 and 50 years old
- •5. Acne severity from 1 to 3 according to IGA, (Investigator’s Global Assessment) severity scale,
- •6. Subjects who have not been recently involved in any other similar study
- •7. Willingness to use for face care only the creams that will be consigned at the beginning of the study
- •8. Willingness to submit before and after pictures
- •9. Willingness to use during all the study period only the products to be tested
- •10. Willingness not to use similar products that could interfere with the product to be tested
- •11. Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, etc.)
- •12. Subject is under effective contraception (oral/not oral); not expected to be changed during the trial
- •13. Subject aware of the study procedures and having signed an informed consent form
- •14. Subjects who accept not to expose in an intensive way to UV rays during the whole study duration
排除标准
- •1. Subjects who do not meet the inclusion criteria
- •2. Pregnant/breastfeeding female or who have planned pregnancy during the study period
- •3. Subjects under systemically pharmacological treatment
- •4. Subjects under locally pharmacological treatment on the skin area monitored during the test
- •5. Subjects with congenital or acquired immunodeficiency
- •6. Subjects under treatment with food supplements which could interfere with the functionality of the product under study
- •7. Subjects who show other skin alterations on the monitored area
- •8. Subjects considered as not adequate to participate in the study by the investigator
- •9. Subjects with known or suspected sensitization to one or more test formulation ingredients
- •10. Adult protected by law (under control or hospitalized in public or private institutions for
- •reasons other than research, or incarcerated)
- •11. Subjects not able to communicate or cooperate with the investigator for problems related to language, mental retardation, or impaired brain function
研究者
相似试验
已完成
2 期
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT03662542Janssen Research & Development, LLC214
尚未招募
2 期
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell Carcinoma (OSCC)Oropharyngeal Squamous Cell Carcinoma (SCC)Resectable Oral and Oropharyngeal Squamous Cell CarcinomaRecurrent Oral and Oropharyngeal Squamous Cell CarcinomaNCT06728618Shanghai Zhongshan Hospital28
已完成
1 期
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid LeukaemiaAcute Myeloid LeukaemiaNCT04629443Institut de Recherches Internationales Servier17
已完成
不适用
Investigating the effect of combined action observation therapy and eccentric exercises in the treatment of mid-portion achilles tendinopathyMid-portion Achilles TendinopathyMusculoskeletal DiseasesISRCTN58161116niversity College Dublin30
终止
2 期
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.Metastatic Colorectal CancerNCT00531115Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)28
